US Stock MarketDetailed Quotes

ESPR Esperion Therapeutics

Watchlist
  • 0.9549
  • -0.0050-0.52%
Trading Apr 30 14:35 ET
189.21MMarket Cap-3.41P/E (TTM)

About Esperion Therapeutics Company

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Company Profile

SymbolESPR
Company NameEsperion Therapeutics
Listing DateJun 26, 2013
Issue Price14.00
Founded1998
CEOMr. Sheldon L. Koenig
MarketNASDAQ
Employees304
Fiscal Year Ends12-31
Address3891 Ranchero Drive,Suite 150
CityAnn Arbor
ProvinceMichigan
CountryUnited States of America
Zip Code48108
Phone1-734-887-3903

Company Executives

  • Name
  • Position
  • Salary
  • Sheldon L. Koenig
  • Director, President and Chief Executive Officer
  • 3.18M
  • Benjamin Halladay
  • Chief Financial Officer and Principal Accounting Officer
  • 1.37M
  • J. Martin Carroll
  • Chairman of the Board
  • 194.83K
  • Nicole Vitullo
  • Independent Director
  • 173.66K
  • Robert E. Hoffman, C.P.A.
  • Independent Director
  • --
  • Dr. Antonio M. Gotto,Jr,M.D.,D.Phil.
  • Independent Director
  • 159.83K
  • Tracy M. Woody
  • Independent Director
  • 176.16K
  • Stephen C. Rocamboli
  • Independent Director
  • 172.33K
  • Seth H.Z. Fischer
  • Independent Director
  • 177.33K
  • Jay P. Shepard
  • Independent Director
  • 174.83K
  • Alan Fuhrman
  • Independent Director
  • 182.33K
  • Benjamin O. Looker
  • General Counsel
  • 1.13M

Market Insights

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.